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Screening for potential plasmid integration by Southern blot or PCR. Genomic DNA was 
extracted from CoMiP-transfected cell line, lentivirus-infected control cell line, and negative 
control fibroblast cell line. Twenty µg of genomic DNA from each sample were digested with 
SpeI overnight at 37˚C. SpeI cut the CoMiP expression cassette once and linearized the vector. 
Digested DNA samples were separated by electrophoresis on a 1% agarose gel and blotted onto a 
nitrocellulose membrane. 0.1 ng SpeI-digested or non-digested CoMiP vector DNA was 
incorporated into the same Southern gel as linearized or non-linearized non-integrating control. 
Twenty µg SpeI-digested genomic DNA of negative control fibroblasts were mixed with one 
CoMiP vector linearized non-integrating control sample to imitate genomic DNA extracted from 
cell lines. The Southern blot membrane was hybridized with [P-32] dCTP-labeled 702 bp 
tdTomato probe (PCR product by using forward primer “5’GTGAGCAAGGGCGAGGAGG3’” 
and reverse primer “5’CTTGTACAGCTCGTCCATGC3’”) overnight at 65°C. CoMiP signals 
were detected through phosphoimaging. The PCR screening was performed by using the 
standard Taq polymerase protocol and primers summarized in Supplementary Table 1. 
 
Analysis of protein expression differences by Western blot. Cells were harvested in RIPA 
lysis buffer (Sigma) supplemented with protease (Complete Mini; Roche) and phosphatase 
inhibitors (Phosphatase Inhibitor Cocktail I and II; Sigma). Five to twenty µg of total protein 
were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes following 
the protocol of the manufacturer (Invitrogen XCell SureLock™ Mini Cell Electrophoresis and 
Wet Blot System). Membranes were incubated overnight with the primary antibodies and with 
appropriate peroxidase-conjugated secondary antibodies for 45 min. Chemiluminescence 
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(PerkinElmer) reaction was carried out. Primary antibodies used were against OCT4 (R&D 
Systems, AF1759) and α-tubulin (Sigma). Secondary antibodies were anti-goat and anti-mouse 
horseradish peroxidase (Jackson Laboratories). 
 
Immunofluorescence of human iPSCs. Human iPSCs (1x104 cells/chamber) derived with the 
different methods were seeded on Matrigel coated 8-chamber slides in a final volume of 200 µL 
of E8 medium. After 24-72 hr, cells were washed 3X with PBS and fixed for 20 min at RT using 
100 µL 4% paraformaldehyde (PFA) in PBS. Thereafter, cells were washed with 200 µL PBS 
(3X) and incubated for 15 min at RT with 100 µL of permeabilization solution (0.2% Triton X-
100 in PBS). Next, cells were washed twice with PBS and incubated with blocking solution (2% 
BSA or 4% goat serum or 2% FBS in PBS), for 1 hr at RT or overnight at 4ºC. After another 
wash step (PBS), cells were covered overnight at 4°C with primary antibody diluted 
appropriately in blocking solution (100 µL per chamber). The following day, slides were washed 
4X for 10 min using 1% goat serum, 0.1% Tween-20 in PBS. Afterwards, cells were incubated 
with the appropriate secondary antibody diluted in blocking solution, for 1 hr at RT (100 µL per 
chamber). After a final wash step (4X, 1% goat Serum, 0.1% Tween-20 in PBS, for 10 min), 
chambers were removed and cells were incubated with a small amount of Vectashield mounting 
medium with DAPI. Afterwards, cells were covered and sealed using nail varnish.  
 
Immunofluorescence of human iPSC-derived cardiomyocytes. iPSC-CMs were passaged 
onto Matrigel-coated coverslips and immunohistochemistry was performed as described before 
(Lan et al., Cell Stem Cell 2013). Samples were analyzed using a LSM 510 Meta inverted 
confocal microscope (Carl Zeiss) and ZEN software (Carl Zeiss). 
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Karyotype analysis of human iPSCs. The iPSC lines were detached from the culture plate 
using Accutase for 8 min and centrifuged at 300 g for 3 min. iPSC pellets were resuspended in 
200 µL of PBS and DNA was isolated using the DNeasy blood and tissue kit (Qiagen, Valencia, 
CA). DNA was submitted to the Stanford Functional Genomics Facility for SNP karyotyping 
using the HuCytoSNP-12 chip (Illumina). CNV and SNP visualization were performed using 
KaryoStudio v1.4 (Illumina).	  
 
RNA extraction and quantitative real-time PCR. Total RNA was isolated using RNeasy Plus 
Mini Kit (Qiagen 74134). The reverse transcriptase PCR was performed using the iScript™ 
cDNA Synthesis Kit (Bio-rad 170-8891). The quantitative real-time PCR was performed using 
the iQ SYBR Green Supermix (Bio-rad 170-8882) and a CFX96™ real-time PCR detector (Bio-
Rad). The relative mRNA levels were normalized to the values of 18S mRNA for each reaction. 
Primer information shown in Supplementary Table 2.	  
 
Chromatin immunoprecipitation assays. The antibodies used in ChIP assays were 39159 for 
H3 tri-methylation lysine4 (Active Motif), 39155 for H3 tri-methylation lysine27 (Active Motif), 
and sc-2027 for control IgG (Santa Cruz Biotechnology). Antibodies were incubated with 
Dynabeads (Invitrogen, 10003D) for 12 hr at 4°C. The main fraction of the crosslinked and 
sheared chromatin was incubated with the antibody-conjugated Dynabeads and a small aliquot of 
the chromatin was used as an input control. After an overnight incubation at 4°C, the incubated 
beads were rinsed with sonication buffer (50 mM Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM PMSF), high salt buffer (50 mM 
Hepes pH 7.9, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% 
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SDS, 0.5 mM PMSF), and LiCl buffer (20 mM Tris, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% 
NP-40, 0.5% Na-deoxycholate, 0.5 mM PMSF). The washed beads were incubated with an 
elution buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 1% SDS, 50 mM NaHCO3) for 1 hr at 65°C 
and then de-crosslinked overnight with 5M NaCl at 65°C. The immunoprecipitated DNA was 
treated with Rnase A and Proteinase K, and purified by ChIP DNA clean and concentrator 
(Zymo Research D5205). The immunoprecipitated and input DNA was analyzed by quantitative 
real-time PCR. Primer information is shown in Supplementary Table 3.	  	  
Fluorescent activated cell sorting (FACS). Transfected fibroblasts were detached using 
TrypLE (Life Technologies) and stained when indicated with propidium iodide (PI) to determine 
the percentage of viable cells.  Samples were analyzed using a LSR Fortessa Analyzer and  BD 
FACSDiva, as well as FlowJo softwares. 
 
Scorecard pluripotency and differentiation panel. iPSC or iPSC-derived embryoid bodies (10 
days old) were harvested either using Trizol or RNeasy Mini Kit (QIAGEN). Subsequently, 
samples were further processed as described in TaqMan® hPSC Scorecard™ Panel User Guide 




SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. Comparison of the transfection efficiencies using different 
reprogramming plasmids. (A-B) FACS blot showing the comparable transfection efficiencies of 
CoMiP, CoMiC, and 3 Yamanaka factors.  
 
Supplementary Figure 2. Cell viability after transfection of the individual reprogramming 
plasmids. (A-C) Using propidium iodide staining followed by FACS analysis, we observed the 
highest cell survival after transfecting with the CoMiP reprogramming plasmid. 
 
Supplementary Figure 3. Analysis of the transient transgene expression levels in HEK 293 cells 
produced by the different constructs used in this study (minicircle, CoMiP, and regular Plasmid). 
(A) Codon-optimized reprogramming cassette OKSM cloned into minicircle, mini-intronic 
plasmid (MiP), or regular plasmid backbone were transfected into HEK 293 cells. Western blot 
illustrates that the level of protein expression is dependent on the plasmid backbone. All 
constructs had the same SFFV promoter sequence driving the OKSM expression. (B) 
Comparison of the transgene expression efficiency mediated by different constructs (Yamanaka 
episomal plasmids, pCXL, and the 4-in-1 CoMiP) showed superior OCT4 protein expression 
(Western blot) levels by the CoMiP construct. 
 
Supplementary Figure 4. Schematic overview of the 4-in-1 codon-optimized reprogramming 
plasmid (CoMiP). The plasmid-defining intronic sequence contains the antibiotic-free bacterial 
selection cassette.  The strong spleen focus forming virus (SFFV) promoter drives the expression 
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of the reprogramming factors that are linked to a fluorescent marker (tdTomato) through an 
internal ribosomal entry site (IRES) site. Addition of a p53 shRNA further increased the 
reprogramming efficiency.    
 
Supplementary Figure 5. (A) Immunofluorescence staining (TRA-1-60, OCT4 and nuclear 
DAPI staining) and (B) in vivo teratoma differentiation assays confirmed pluripotency of the 
iPSCs derived with the 3 individual Yamanaka episomal plasmids pCXLE-hOCT3/4-shRNA 
p53, pCXLE-hl-Myc/LIN28, and pCXLE-hSOX2/KLF4. (C) The pluripotent identity of the 
iPSCs derived with the 4-in-1 minicircle (CoMiC) was confirmed by Brightfield picture 
Immunofluorescence staining (OCT4 and NANOG) and (D) in vivo teratoma differentiation 
assays. 
 
Supplementary Figure 6. Comparison of the three different plasmid-based reprogramming 
strategies on human fibroblasts. CoMiC, CoMiP, and episomal plasmids were transiently 
introduced into fibroblasts of (A) young (18-23 years) versus (B) old (50-70 years) human 
subjects using lipofection. Using the 4-in-1 CoMiP plasmid, we were able to derive 3-10 iPSC 
colonies after transfecting 2x105 cells in a single attempt, whereas we could not generate any 
iPSCs by using a single-pass lipofection with the minicircle or episomal plasmid. Representative 
pictures showing different AP positive cell colonies (magnification) and a proliferating pre-iPSC 
clone. 
 
Supplementary Figure 7. Analysis of the reprogramming efficiencies under chemical defined 
condition and influences of the innate immune response.  (A) Robust 4-in-1 CoMiP-mediated 
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reprogramming efficiency under chemical defined conditions using Synthemax and chemical 
defined media E7. However, reprogramming using fully chemical defined condition reduced the 
overall number of AP-positive colonies by roughly 50%. (B) Manipulating the innate immune 
response had no statistically significant influence on the 4-in-1 CoMiP-mediated reprogramming 
efficiency. Activation of the innate immune response by poly I:C slightly reduced the number of 
AP-positive cells, whereas inhibition of the innate immune response by B18R slightly enhanced 
the number of AP-positive cells. Statistical significance was analyzed using the student’s t-test 
and expressed as a P-value. *P < 0.05; **P < 0.01; ns, not significant. 
 
Supplementary Figure 8. Reprogramming with 4-in-1 CoMiP plasmid allows derivation of 
integration-free iPSCs. (A) Southern blot experiments were used to screen different 4-in-1 
CoMiP-derived iPSCs for potential integrations. Lanes 0 and 1 represent control DNA either 
from untransfected 4-in-1 CoMiP plasmid DNA (internal control for the Southern blot probe 
targeting the tdTomato sequence, 0) or from a lentiviral-derived iPSC line (1, integration 
control). Clones 2, 4, and 6 were integration-free and also free of residual plasmid DNA. Clones 
3, 5 and 7 might be free of integration but still had residual CoMiP DNA within the individual 
clones as circulating episomes. The clone at line 8 shows multiple genomic integrations. (B) 
PCR-based screening method for potential integration using primers targeting the junction region 
between OCT4 and KLF4 within the 4-in-1 CoMiP plasmid mainly confirms the Southern blot 




Supplementary Figure 9. PBMC, keratinocytes, and renal epithelia-derived iPSCs are 
pluripotent. After injection into nude mice, all of the individual iPSCs generated teratomas 
representing all 3 germ layers. 
  
Supplementary Figure 10. Pluripotency analysis of the PBMC, keratinocytes and renal 
epithelia-derived iPSCs using the TaqMan® hPSC Scorecard™ Panel. (A) The individual iPSC 
lines showed overall expression scores of pluripotency genes that were comparable to the 
reference. After spontaneous differentiation into embryoid bodies, the expression of the self-
renewal genes were down-regulated and the expression of genes of the 3 germ layers were up-
regulated. (B) All cell lines showed a high propensity to differentiate into the 3 germ layers.     
 
Supplementary Figure 11. CoMiP reprogramming of human keratinocytes. (A) Timeline shows 
the expected morphological changes of 4-in-1 CoMiP-transfected and reprogrammed human 
keratinocytes. (B) The expression of different pluripotency related marker genes within the 
keratinocyte-derived iPSCs was confirmed by immunofluorescence staining for OCT4, NANOG, 
and TRA-1-81. 
 
Supplementary Figure 12. The pluripotency of the 4-in-1 CoMiP-derived murine iPSC cell 
lines were confirmed by in vitro and in vivo experiments. (A) Immunofluorescence staining 
showed the expression of different pluripotency associated marker genes (Nanog, Oct4, and 
SSEA-1). (B) Teratoma assay confirmed the pluripotent potential of murine iPSCs to form 




Supplementary Figure 13. Summarizing the study design of the comparison of the three 
reprogramming methods. (A) One single nucleofection was sufficient enough to reprogram 
human adult fibroblast using any one of the three methods. Using the 4-in-1 CoMiP vector 
system was faster than the episomal or minicircle reprogramming methods without generating 
intermediate iPSCs (blue cell cluster) but only fully reprogrammed iPSCs (green cell cluster). 
(B) Interestingly, only the 4-in-1 CoMiP vector system was able to induce pluripotency in adult 
human fibroblasts by using one single lipofection to deliver the reprogramming plasmids. AP, 





SUPPLEMENTARY TABLES  
Supplementary Table 1 
 
Primer sequences for integration test:  
OCT4-KLF4 Set2   F: GGCAGAAGGGCAAGAGAAG     
    R: CTCCCGCCATCTGTTGTTAG 
 
Supplementary Table 2 
Primer sequences for qPCR:  
 
NANOG F: TTCACTGTGTTAGCCAGGATG  R: ATGTCTTTTCTAGGCAGGGC 
SOX2  F:GAGAAGTTTGAGCCCCAGG  R: AGAGGCAAACTGGAATCAGG 
REX1   F: TTCTCCTTTGTTTTACGTTTGGG    R: AGATCACACCATTGCACTCC 
KFL4    F: ACCTACACAAAGAGTTCCCATC    R: TGTGTTTACGGTAGTGCCTG 
OCT4   F: CCATGCATTCAAACTGAGGTG     R: CCTTTGTGTTCCCAATTCCTTC 
TNNT2   F: AGCGGAAAAGTGGGAAGAG    R: TCCAAGTTATAGATGCTCTGCC 
MYH6   F: GGGACAGTGGTAAAAGCAAAG     R: ACAAAGTGAGGATGGGTGG 




Supplementary Table 3 
Primer sequences for ChIP-qPCR:  
NANOG-ChIP    F: AGAGAAGGAGAGAGGGTTAAGG    
    R: GCAGGTGCCACCAAGTTAT 
OCT4-ChIP   F: CTTGGGTCTGATAAGGGTCAAA     
    R: CAGGGTCTCTCACATCTCCTA 
SOX2-ChIP   F: CATGAACGGCTGGAGCAA        
    R: GCTGGTCATGGAGTTGTACTG 
REX1-ChIP   F: AAGTGTCTGGCGGTGATTT       
     R: CTCCAGAGATAAGAGGAGAGGAA 
NKX2.5-ChIP   F: GTAAGAGCGGCTTGACCTAC       







Supplementary Table 4 (Scorecard results) 
Scorecard Analysis of iPSC Lines (Fold-change) 
 
       
Target 
Name Category PBMC Cl1 Keratinocyte Renal  PBMC Cl2  
CDH9 Ectoderm 0,30 0,07 0,18 0,36 
COL2A1 Ectoderm 3,43 0,39 1,57 2,18 
DMBX1 Ectoderm 0,06 0,09 0,46 0,13 
DRD4 Ectoderm 0,08 0,01 0,09 0,06 
EN1 Ectoderm 1,51 0,63 7,21 1,38 
LMX1A Ectoderm 0,37 0,12 1,50 0,43 
MAP2 Ectoderm 5,65 0,58 0,18 6,06 
MYO3B Ectoderm 2,89 0,61 1,13 2,85 
NOS2 Ectoderm 0,15 0,22 0,26 0,11 
NR2F1/NR
2F2 Ectoderm 0,39 0,04 0,08 0,46 
NR2F2 Ectoderm 19,76 0,75 4,93 19,91 
OLFM3 Ectoderm 0,46 0,51 0,52 0,48 
PAPLN Ectoderm 0,89 0,23 1,45 0,84 
PAX3 Ectoderm 111,11 1,73 4,04 73,80 
PAX6 Ectoderm 2,17 0,15 0,27 2,62 
POU4F1 Ectoderm 0,64 0,72 1,90 0,07 
PRKCA Ectoderm 0,37 0,28 0,27 0,36 
SDC2 Ectoderm 9,79 6,22 16,61 10,69 
SOX1 Ectoderm 0,03 0,04 0,07 0,20 
TRPM8 Ectoderm 25,24 2,40 1,28 28,11 
WNT1 Ectoderm 0,22 0,24 0,47 0,18 
ZBTB16 Ectoderm 0,64 0,25 1,27 0,72 
AFP Endoderm 0,01 0,01 0,01 0,00 
CABP7 Endoderm 0,00 0,04 0,83 0,00 
CDH20 Endoderm 1,04 0,47 0,46 1,00 
CLDN1 Endoderm 1,01 0,47 0,56 1,22 
CPLX2 Endoderm 0,02 0,05 0,02 0,01 
ELAVL3 Endoderm 0,07 0,70 4,88 0,07 
EOMES Endoderm 0,03 0,02 0,06 0,04 
FOXA1 Endoderm 0,45 0,14 0,64 0,05 
FOXA2 Endoderm 0,00 0,60 0,01 0,00 
FOXP2 Endoderm 0,37 0,37 0,42 0,33 
GATA4 Endoderm 0,02 0,04 0,24 0,01 
GATA6 Endoderm 0,00 0,01 0,03 0,01 
HHEX Endoderm 0,07 0,09 0,48 0,07 
HMP19 Endoderm 0,42 1,24 1,74 0,34 
HNF1B Endoderm 0,21 0,03 0,17 0,12 
HNF4A Endoderm 0,00 0,27 0,06 0,00 
KLF5 Endoderm 1,39 1,95 3,05 1,30 
LEFTY1 Endoderm 0,04 1,07 0,52 0,05 
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LEFTY2 Endoderm 0,22 0,95 0,60 0,24 
NODAL Endoderm 0,01 0,26 0,27 0,01 
PHOX2B Endoderm 0,13 0,14 0,28 0,11 
POU3F3 Endoderm 0,53 0,06 0,67 0,51 
PRDM1 Endoderm 0,14 0,03 0,07 0,13 
RXRG Endoderm 1,93 0,20 0,05 1,47 
SOX17 Endoderm 0,02 0,17 1,97 0,18 
SST Endoderm 12,84 4,76 1,63 16,16 
FGF4 Mesendoderm 0,12 13,55 51,21 0,08 
GDF3 Mesendoderm 0,68 11,90 8,75 0,87 
NPPB Mesendoderm 0,02 0,08 0,01 0,09 
NR5A2 Mesendoderm 159,74 372,92 532,81 160,16 
PTHLH Mesendoderm 1,58 0,29 0,58 1,41 
T Mesendoderm 0,00 0,00 0,00 0,01 
ABCA4 Mesoderm 1,64 1,58 2,80 1,90 
ALOX15 Mesoderm 0,12 0,21 0,41 0,15 
BMP10 Mesoderm 0,28 0,29 0,58 0,22 
CDH5 Mesoderm 54,01 1,98 1,73 54,66 
CDX2 Mesoderm 0,32 0,26 0,25 0,26 
COLEC10 Mesoderm 0,57 0,48 2,21 0,77 
ESM1 Mesoderm 0,50 1,02 1,81 0,66 
FCN3 Mesoderm 1,12 1,41 6,03 1,13 
FOXF1 Mesoderm 0,91 2,22 5,59 1,47 
HAND1 Mesoderm 0,02 0,38 1,31 0,09 
HAND2 Mesoderm 1,62 2,85 3,59 0,48 
HEY1 Mesoderm 0,82 0,27 0,37 0,79 
HOPX Mesoderm 0,28 2,36 4,67 4,87 
IL6ST Mesoderm 1,17 0,73 1,32 1,11 
NKX2-5 Mesoderm 0,87 4,64 1,96 0,38 
ODAM Mesoderm 0,25 2,53 3,29 1,42 
PDGFRA Mesoderm 0,09 1,02 0,74 0,10 
PLVAP Mesoderm 0,89 0,32 0,77 0,81 
RGS4 Mesoderm 0,15 1,06 0,45 0,15 
SNAI2 Mesoderm 3,40 0,29 0,20 3,79 
TBX3 Mesoderm 0,02 0,08 0,20 0,02 
TM4SF1 Mesoderm 11,15 0,60 0,21 14,61 
CXCL5 Self-renewal 23,67 4,46 5,59 31,89 
DNMT3B Self-renewal omitted omitted omitted omitted 
HESX1 Self-renewal omitted omitted omitted omitted 
IDO1 Self-renewal 0,15 0,30 0,33 0,17 
LCK Self-renewal 1,67 1,66 2,59 1,27 
NANOG Self-renewal 0,49 1,07 1,55 0,40 
POU5F1 Self-renewal 0,31 0,70 0,92 0,30 
SOX2 Self-renewal 0,53 0,52 1,07 0,69 





      
 
 










fc > 100 Upregulated 
    10 < fc <= 
100   
    2 < fc <= 10   
    0.5 <= fc <= 
2 Comparable 
    0.1 <= fc < 
0.5   
    0.01 <= fc < 
0.1   
    fc < 0.01 Downregulated 
    omitted   
    
  
Scorecard Analysis of Embryoid Bodies (Fold-change) 
 
Experiment 
Filename         
Target Name Category PBMC Cl1 Renal  PBMC Cl2 
CDH9 Ectoderm 0,26 0,02 0,51 
COL2A1 Ectoderm 31,89 0,65 21,25 
DMBX1 Ectoderm 1,05 0,01 0,74 
DRD4 Ectoderm 0,33 0,27 1,39 
EN1 Ectoderm 102,37 3,75 5,81 
LMX1A Ectoderm 157,80 0,22 81,69 
MAP2 Ectoderm 25,76 0,21 10,09 
MYO3B Ectoderm 21,22 20,75 25,59 
NOS2 Ectoderm 0,11 14,22 0,40 
NR2F1/NR2F2 Ectoderm 84,81 0,17 133,13 
NR2F2 Ectoderm 890,29 1.357,35 872,57 
OLFM3 Ectoderm 48,53 0,52 44,44 
PAPLN Ectoderm 0,31 0,46 0,31 
PAX3 Ectoderm 672,77 7,25 2.505,62 
PAX6 Ectoderm 26,99 0,12 151,11 
POU4F1 Ectoderm 39,66 1,16 15,34 
PRKCA Ectoderm 1,52 0,26 0,29 
SDC2 Ectoderm 52,75 2,52 10,21 
SOX1 Ectoderm 0,94 0,06 1,96 
TRPM8 Ectoderm 86,50 1,01 12,72 
WNT1 Ectoderm 3.542,76 65,58 3.343,77 
ZBTB16 Ectoderm 9,25 0,40 18,89 
AFP Endoderm 18,80 1,46 0,01 
CABP7 Endoderm 3,26 0,32 4,00 
CDH20 Endoderm 7,75 0,39 53,48 
CLDN1 Endoderm 3,39 10,65 7,20 
CPLX2 Endoderm 10,33 0,13 1,36 
ELAVL3 Endoderm 13,76 0,30 5,42 
EOMES Endoderm 0,03 0,37 0,09 
FOXA1 Endoderm 3,22 0,38 0,24 
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FOXA2 Endoderm 0,81 0,49 0,01 
FOXP2 Endoderm 19,19 0,64 10,72 
GATA4 Endoderm 0,79 1,13 0,06 
GATA6 Endoderm 0,74 2,07 0,35 
HHEX Endoderm 0,89 0,19 0,06 
HMP19 Endoderm 50,30 5,74 8,28 
HNF1B Endoderm 5,70 1,22 2,80 
HNF4A Endoderm 2,79 1,13 0,06 
KLF5 Endoderm 2,74 15,93 12,36 
LEFTY1 Endoderm 0,01 0,03 0,02 
LEFTY2 Endoderm 0,23 0,11 0,74 
NODAL Endoderm 0,01 0,06 0,06 
PHOX2B Endoderm 10,11 0,24 7,21 
POU3F3 Endoderm 3,03 0,01 1,77 
PRDM1 Endoderm 0,42 1,29 0,47 
RXRG Endoderm 94,86 12,02 35,09 
SOX17 Endoderm 36,51 13,05 0,26 
SST Endoderm 133,19 32,06 132,01 
FGF4 Mesendoderm 0,04 4,87 0,21 
GDF3 Mesendoderm 0,07 3,76 0,46 
NPPB Mesendoderm 0,58 3,25 9,02 
NR5A2 Mesendoderm 17,90 9,67 98,89 
PTHLH Mesendoderm 120,07 15,16 52,43 
T Mesendoderm 0,00 0,04 0,01 
ABCA4 Mesoderm 12,06 30,33 26,86 
ALOX15 Mesoderm 3,21 6,63 1,33 
BMP10 Mesoderm 111,32 264,25 21,54 
CDH5 Mesoderm 25,86 3.381,32 15,19 
CDX2 Mesoderm 6,60 13,44 5,34 
COLEC10 Mesoderm 10,68 0,82 3,15 
ESM1 Mesoderm 68,94 8,96 19,25 
FCN3 Mesoderm 8,69 14,21 0,29 
FOXF1 Mesoderm 25,80 70,37 3,14 
HAND1 Mesoderm 49,83 144,92 34,07 
HAND2 Mesoderm 183,24 242,43 18,45 
HEY1 Mesoderm 7,99 107,20 9,13 
HOPX Mesoderm 125,69 131.646,05 34,24 
IL6ST Mesoderm 12,05 12,50 4,29 
NKX2-5 Mesoderm 8,41 1,69 1,61 
ODAM Mesoderm 14,39 752,49 7,16 
PDGFRA Mesoderm 4,56 1,93 1,64 
PLVAP Mesoderm 18,24 5,26 1,05 
RGS4 Mesoderm 69,10 71,92 7,93 
SNAI2 Mesoderm 235,71 28,52 41,22 
TBX3 Mesoderm 5,81 190,57 9,69 
TM4SF1 Mesoderm 72,18 22,96 6,56 
CXCL5 Self-renewal 0,23 0,07 0,87 
DNMT3B Self-renewal 0,00 0,04 0,01 
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HESX1 Self-renewal 0,02 0,02 0,02 
IDO1 Self-renewal 0,00 0,03 0,00 
LCK Self-renewal 0,00 0,05 0,01 
NANOG Self-renewal 0,00 0,06 0,04 
POU5F1 Self-renewal 0,02 0,13 0,08 
SOX2 Self-renewal 0,18 0,02 0,18 
TRIM22 Self-renewal 0,32 0,20 0,29 
     
 
 
Experiment Filename     
Target Name Category Keratinocyte  
CDH9 Ectoderm 0,50 
COL2A1 Ectoderm 0,14 
DMBX1 Ectoderm 0,42 
DRD4 Ectoderm 0,27 
EN1 Ectoderm 32,66 
LMX1A Ectoderm 0,76 
MAP2 Ectoderm 1,49 
MYO3B Ectoderm 26,88 
NOS2 Ectoderm 0,20 
NR2F1/NR2F2 Ectoderm 0,25 
NR2F2 Ectoderm 17,67 
OLFM3 Ectoderm 5,33 
PAPLN Ectoderm 1,76 
PAX3 Ectoderm 11,03 
PAX6 Ectoderm 0,40 
POU4F1 Ectoderm 4,19 
PRKCA Ectoderm 1,03 
SDC2 Ectoderm 3,44 
SOX1 Ectoderm 1,77 
TRPM8 Ectoderm 4,45 
WNT1 Ectoderm 11,42 
ZBTB16 Ectoderm 0,69 
AFP Endoderm 0,26 
CABP7 Endoderm 3,39 
CDH20 Endoderm 1,37 
CLDN1 Endoderm 3,31 
CPLX2 Endoderm 0,56 
ELAVL3 Endoderm 2,16 
EOMES Endoderm 1,53 
FOXA1 Endoderm 0,45 
FOXA2 Endoderm 0,75 
FOXP2 Endoderm 8,91 
GATA4 Endoderm 1,35 
GATA6 Endoderm 0,70 
HHEX Endoderm 0,07 
HMP19 Endoderm 2,54 
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HNF1B Endoderm 3,36 
HNF4A Endoderm 0,21 
KLF5 Endoderm 89,05 
LEFTY1 Endoderm 1,13 
LEFTY2 Endoderm 7,04 
NODAL Endoderm 0,19 
PHOX2B Endoderm 6,81 
POU3F3 Endoderm 0,37 
PRDM1 Endoderm 2,07 
RXRG Endoderm 14,37 
SOX17 Endoderm 22,06 
SST Endoderm 14,66 
FGF4 Mesendoderm 0,61 
GDF3 Mesendoderm 4,36 
NPPB Mesendoderm 0,81 
NR5A2 Mesendoderm 155,79 
PTHLH Mesendoderm 33,61 
T Mesendoderm 0,09 
ABCA4 Mesoderm 28,43 
ALOX15 Mesoderm 1,22 
BMP10 Mesoderm 14,04 
CDH5 Mesoderm 37,38 
CDX2 Mesoderm 6,26 
COLEC10 Mesoderm 22,04 
ESM1 Mesoderm 3,90 
FCN3 Mesoderm 1,10 
FOXF1 Mesoderm 5,87 
HAND1 Mesoderm 257,23 
HAND2 Mesoderm 4,03 
HEY1 Mesoderm 3,16 
HOPX Mesoderm 1.856,77 
IL6ST Mesoderm 8,06 
NKX2-5 Mesoderm 27,79 
ODAM Mesoderm 518,18 
PDGFRA Mesoderm 1,56 
PLVAP Mesoderm 1,14 
RGS4 Mesoderm 7,03 
SNAI2 Mesoderm 5,20 
TBX3 Mesoderm 21,16 
TM4SF1 Mesoderm 8,56 
CXCL5 Self-renewal 5,17 
DNMT3B Self-renewal 0,04 
HESX1 Self-renewal 1,44 
IDO1 Self-renewal 1,11 
LCK Self-renewal 3,26 
NANOG Self-renewal 2,90 
POU5F1 Self-renewal 1,75 
SOX2 Self-renewal 2,88 
18 
 
TRIM22 Self-renewal 5,29 
   
 
 
Fold change legend 
  fc > 100 Upregulated 
 10 < fc <= 100   
 2 < fc <= 10   
 0.5 <= fc <= 2 Comparable 
 0.1 <= fc < 0.5   
 0.01 <= fc < 0.1   
 fc < 0.01 Downregulated 
 omitted   
  
FACS Transfection Efficiency 
3 Yamanaka Factors CoMiC CoMiP 
Reprogramming 
Plasmids 






CoMiP 14.8 28.1 21.45 9.4 
CoMiC 19.9 10.2 15.05 6.86 
3 Yamanaka 
factors 
20.5 12.2 16.35 5.87 
B	  
A	  





















GFP or RFP positve cells 
3 Yamanaka Factors CoMiC CoMiP 
FACS Viability – Propidium Iodide Staining 
Reprogramming 
Plasmids 
Cell number FACS 









CoMiP 245000 230000 96.9 3.1 97.8 2.2 
CoMiC 167500 162500 97.7 2.3 97.4 2.6 
3 Yamanaka 
factors 
130000 140000 97.0 3.0 96.4 3.6 
Reprogramming 
Plasmids 
Relative number of cells alive after transfection 






CoMiP 21.58 20.45 21.02 0.80 
CoMiC 11.55 12.39 11.97 0.60 
3 Yamanaka 
factors 

























Sup	  Figure	  2	  





protein	  expression	   	  0%	   	  64%	   100%	   44%	   	  0%	   	  70%	   	  100%	  
4-­‐in-­‐1	  CoMiP	  
9.4	  kb	  
Sup	  Figure	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SFFV Promoter Intron 
pUC replication origin 
Codon optimized OKSM cassette  IRES tdTomato shRNA p53 
1000 bp 2000 bp 3000 bp 4000 bp 5000 bp 6000 bp 7000 bp 8000 bp 9000 bp 
selection marker (RNA-OUT) 















Fibroblasts	  from	  younger	  human	  subjects	  	  
(18-­‐23	  years)	  
CoMiP	  
3	  Yamanaka	  	  
plasmids	  
Fibroblasts	  from	  older	  human	  subjects	  	  
(50-­‐70	  years)	  
CoMiP	   CoMiC	  
3	  Yamanaka	  	  
plasmids	  
Early	  iPSCs	  
Sup	  Figure	  6	  
CoMiC	  
A	   B	  
Sup	  Figure	  7	  
CoMiP reprogramming and innate immunity 
poly I:C B18R control  
B	  
Fibroblast Media on Synthemax 
  




























1 2 3 4 5 6 7 8 
1  hiPSC  clone 1 (Lentivirus)    
2  miPSC clone 1 (CoMiP, Electroporation) 
3  miPSC clone 2 (CoMiP, Electroporation) 
4  hiPSC clone 1 (CoMiP, Electroporation) 
5  hiPSC clone 2 (CoMiP, Electroporation) 
6  hiPSC clone 3 (CoMiP, Electroporation) 
7  hiPSC clone 4 (CoMiP, Lipofection) 
8  hiPSC clone 5 (CoMiP, Lipofection) 
  Marker 
0  Fibroblasts + CoMiP digested  


































Epithelial-­‐derived	  iPSCs	  (renal)	  
B	  A	   C	  
Sup	  Figure	  9	  
Scorecard	  Pluripotency	  Evalua=on	  





Keratinocyte-derived iPSCs 0,97 3,61 1,09 
Renal-derived iPSCs 0,24 4,67 -0,03 
PBMC-derived iPSCs clone 1 1,71 2,17 0,43 












































Kera=nocyte-­‐derived	  iPSCs	   Renal-­‐derived	  iPSCs	  
PBMC-­‐derived	  iPSCs	  clone	  1	   PBMC-­‐derived	  iPSCs	  clone	  2	  
A	  
Sup	  Figure	  10	  
Keratinocytes Reprogramming Timeline 
A	  
B	   NANOG OCT4 TRA-1-81/DAPI 
Sup	  Figure	  11	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coSOX2   
cM
yc   
IR
ES




   











   
DAPI 
Nanog Oct4 








Sup	  Figure	  12	  
Mouse iPSCs 


























30-50 AP  
Positive Colonies 
























  2-10 AP 
 Positive Colonies Sup	  Figure	  13	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